Production & Sales

Y.S.P. Industries to market TaiGen’s new drug in Malaysia and Singapore

Y.S.P. Industries has entered into an exclusive licensing agreement to develop and market TaiGen Biopharmaceuticals Holdings’ (TaiGen) new drug in Malaysia and Singapore.

BridgeBio and Resilience partner to develop gene therapies

BridgeBio Pharma has entered into a strategic partnership with National Resilience (Resilience) for the manufacturing and advancement of two investigational gene therapies, BBP-812 and BBP-631.

Cambrex concludes capacity expansion at High Point facility in US

Cambrex has concluded the expansion of capacity at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina, US.

Lupin acquires five brands and associated trademark rights from Menarini

Indian pharmaceutical firm Lupin has entered into an agreement to acquire five brands along with associated trademark rights from the units of Menarini -- A. Menarini India Private Limited and A. Menarini Asia-Pacific Holdings.

WuXi XDC opens new GMP facilities in China

WuXi XDC has launched new commercial Good Manufacturing Practices (GMP) facilities in Wuxi, Jiangsu Province, China.

Novo Nordisk launches Wegovy for obese patients in UK

Novo Nordisk has launched Wegovy (semaglutide injection) as an adjunctive treatment for obese patients in the UK.

TheracosBio’s commercialises type 2 diabetes oral tablet

TheracosBio has announced the commercial availability of Brenzavvy (bexagliflozin) oral tablet for the treatment of adults with type 2 diabetes by prescription through the Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs).

Astellas Pharma completes acquisition of Iveric Bio

Astellas Pharma, through its indirect wholly owned subsidiary, Berry Merger Sub, has completed the acquisition of Iveric Bio.

Rosemont Pharmaceuticals acquires Lucis Pharma

Rosemont Pharmaceuticals has acquired Lucis Pharma, which is a specialist pharmaceutical business in the UK, for undisclosed amount.